Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival.

Schultz CR, Golembieski WA, King DA, Brown SL, Brodie C, Rempel SA.

Mol Cancer. 2012 Apr 5;11:20. doi: 10.1186/1476-4598-11-20.

2.

PTEN suppresses SPARC-induced pMAPKAPK2 and inhibits SPARC-induced Ser78 HSP27 phosphorylation in glioma.

Alam R, Schultz CR, Golembieski WA, Poisson LM, Rempel SA.

Neuro Oncol. 2013 Apr;15(4):451-61. doi: 10.1093/neuonc/nos326. Epub 2013 Feb 3.

3.

Deletion of the SPARC acidic domain or EGF-like module reduces SPARC-induced migration and signaling through p38 MAPK/HSP27 in glioma.

McClung HM, Golembieski WA, Schultz CR, Jankowski M, Schultz LR, Rempel SA.

Carcinogenesis. 2012 Feb;33(2):275-84. doi: 10.1093/carcin/bgr276. Epub 2011 Nov 23.

4.

HSP27 mediates SPARC-induced changes in glioma morphology, migration, and invasion.

Golembieski WA, Thomas SL, Schultz CR, Yunker CK, McClung HM, Lemke N, Cazacu S, Barker T, Sage EH, Brodie C, Rempel SA.

Glia. 2008 Aug 1;56(10):1061-75. doi: 10.1002/glia.20679.

PMID:
18442089
5.

PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling.

Thomas SL, Alam R, Lemke N, Schultz LR, Gutiérrez JA, Rempel SA.

Neuro Oncol. 2010 Sep;12(9):941-55. doi: 10.1093/neuonc/noq048. Epub 2010 May 14.

6.

Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.

Choi EJ, Cho BJ, Lee DJ, Hwang YH, Chun SH, Kim HH, Kim IA.

BMC Cancer. 2014 Jan 13;14:17. doi: 10.1186/1471-2407-14-17.

7.

Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch.

Hayashi N, Peacock JW, Beraldi E, Zoubeidi A, Gleave ME, Ong CJ.

Cell Death Differ. 2012 Jun;19(6):990-1002. doi: 10.1038/cdd.2011.184. Epub 2011 Dec 16.

8.

HSP27 phosphorylation modulates TRAIL-induced activation of Src-Akt/ERK signaling through interaction with β-arrestin2.

Qi S, Xin Y, Qi Z, Xu Y, Diao Y, Lan L, Luo L, Yin Z.

Cell Signal. 2014 Mar;26(3):594-602. doi: 10.1016/j.cellsig.2013.11.033. Epub 2013 Dec 2.

PMID:
24308965
9.

Knockdown of secreted protein acidic and rich in cysteine (SPARC) expression diminishes radiosensitivity of glioma cells.

Liu H, Zhang H, Jiang X, Ma Y, Xu Y, Feng S, Liu F.

Cancer Biother Radiopharm. 2011 Dec;26(6):705-15. doi: 10.1089/cbr.2011.0987.

PMID:
22145659
10.

Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27.

Sang DP, Li RJ, Lan Q.

Acta Pharmacol Sin. 2014 Jun;35(6):832-8. doi: 10.1038/aps.2014.22.

11.

Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.

Shi Q, Bao S, Song L, Wu Q, Bigner DD, Hjelmeland AB, Rich JN.

Oncogene. 2007 Jun 14;26(28):4084-94. Epub 2007 Jan 8.

PMID:
17213807
12.

Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.

Fukai J, Koizumi F, Nakao N.

PLoS One. 2014 Aug 11;9(8):e104538. doi: 10.1371/journal.pone.0104538. eCollection 2014.

13.

Phosphorylation of AKT induced by phosphorylated Hsp27 confers the apoptosis-resistance in t-AUCB-treated glioblastoma cells in vitro.

Li R, Li J, Sang D, Lan Q.

J Neurooncol. 2015 Jan;121(1):83-9. doi: 10.1007/s11060-014-1610-3. Epub 2014 Sep 9.

PMID:
25200832
14.

Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.

Liu X, Wang L, Chen J, Ling Q, Wang H, Li S, Li L, Yang S, Xia M, Jing L.

Mol Med Rep. 2015 Feb;11(2):1516-22. doi: 10.3892/mmr.2014.2811. Epub 2014 Oct 29.

PMID:
25351348
15.

SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival.

Fenouille N, Puissant A, Tichet M, Zimniak G, Abbe P, Mallavialle A, Rocchi S, Ortonne JP, Deckert M, Ballotti R, Tartare-Deckert S.

Oncogene. 2011 Dec 8;30(49):4887-900. doi: 10.1038/onc.2011.198. Epub 2011 Jun 20.

PMID:
21685937
16.

TRAIL/MEKK4/p38/HSP27/Akt survival network is biphasically modulated by the Src/CIN85/c-Cbl complex.

Kim J, Kang D, Sun BK, Kim JH, Song JJ.

Cell Signal. 2013 Jan;25(1):372-9. doi: 10.1016/j.cellsig.2012.10.010. Epub 2012 Oct 23.

PMID:
23085457
17.

Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.

Grogan PT, Sarkaria JN, Timmermann BN, Cohen MS.

Invest New Drugs. 2014 Aug;32(4):604-17. doi: 10.1007/s10637-014-0084-7. Epub 2014 Apr 10.

18.

Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation.

Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS, Bigner DD, Wang XF, Rich JN.

J Biol Chem. 2004 Dec 10;279(50):52200-9. Epub 2004 Oct 5.

19.

Downregulation of Hsp27 (HSPB1) in MCF-7 human breast cancer cells induces upregulation of PTEN.

Cayado-Gutiérrez N, Moncalero VL, Rosales EM, Berón W, Salvatierra EE, Alvarez-Olmedo D, Radrizzani M, Ciocca DR.

Cell Stress Chaperones. 2013 Mar;18(2):243-9. doi: 10.1007/s12192-012-0367-x. Epub 2012 Aug 21.

20.

Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.

Sims JT, Ganguly SS, Bennett H, Friend JW, Tepe J, Plattner R.

PLoS One. 2013;8(1):e55509. doi: 10.1371/journal.pone.0055509. Epub 2013 Jan 31.

Supplemental Content

Support Center